Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those ...

“These findings are important for the diabetes community, and add to the existing body of evidence for Tresiba.” Bernstein analyst Ronny Gal figures that, if Tresiba can parlay the safety edge over ...

Novo Nordisk NVO announced headline results from a phase IIIb study (SWITCH 1) on Tresiba, comparing its safety and efficacy to Sanofi’s SNY Lantus for the treatment of patients with type I diabetes.

Concern about overnight hypoglycemic events drives decision-making for patients with type 1 diabetes. For persons with type 1 diabetes (T1D) fear of the overnight hypoglycemic event drives care ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Novo Nordisk says the FDA has accepted its reapplication of its long-acting insulin Tresiba, setting it up for an October decision and a launch yet this year if ...

Novo Nordisk ( NVO) recently presented new data on its type II diabetes drug, Tresiba (degludec), from a one-year extension study, BEGIN ONCE LONG. Data from the study was presented at the 73 rd ...

Novo Nordisk has mounted its European challenge to Sanofi’s Lantus with the launch of its insulin degludec Tresiba in the UK and Denmark ahead of a wider regional launch. Danish pharma company Novo ...

Novo Nordisk has published real world data that it says supports a switch to its new insulin Tresiba. The company claims that UK patients with diabetes who started taking Tresiba (insulin degludec) ...

COPENHAGEN, Nov 29 (Reuters) - Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type ...

Novo-Nordisk (OTCPK:NONOF) has a bigger fight on its hands than perhaps it expected when it pushed Tresiba into the clinic more than a decade ago – and its nemesis is not Sanofi (SNY), but US payers.